Julius Baer has gained FSA approval for its biotechnology fund, making it available to British investors.
The Biotech fund was launched in January 2008 with a euro share class, and until now was only available to investors in Europe. It is a Luxembourg-domiciled Sicav run by Eric Bernhardt and Nathalie Flury.
The fund provides exposure to global companies that develop products and technology for the healthcare, agricultural, food science and environmental sectors.
It will have a bias towards large-cap stocks, but may also hold selected small and mid caps. American stocks will form the largest weighting, but it will also have some exposure to companies in Europe.
The group says that biotechnology a rapidly growing area of the market, with the sector trebling in size in America between 1996 and 2008.